

Figure, Supplemental Digital Content 1. Viral Load Measurements for Participants with Virologic Failure at Week 24.

At week 0, all four participants began ART. Participant 1 was prescribed a five-drug ART regimen that included efavirenz, tenofovir, emtricitabine, maraviroc and raltegravir but was intermittently adherent to this therapy. All ART was discontinued at week 25 when genotypic resistance to efavirenz was detected. The participant restarted ART at week 28 with tenofovir, lamivudine, and ritonavir-boosted lopinavir before achieving virologic suppression below the limit of detection at week 60. Participant 2 was also prescribed the five-drug ART regimen and reported good adherence to therapy but did not achieve sustained virologic suppression by week 24. At week 29, the regimen was changed to tenofovir, lamivudine, and ritonavir-boosted lopinavir and virologic suppression was rapidly achieved. Participant 3 was prescribed the five-drug ART regimen but was intermittently adherent to therapy and underwent regimen changes at weeks 27, 36, and 60 due to complaints of ART side effects. Adherence eventually improved and the participant achieved virologic suppression on a regimen of tenofovir, emtricitabine, and ritonavir-boosted lopinavir. No genotypic evidence of resistance was ever detected. Participant 4 was prescribed efavirenz, tenofovir and lamivudine. The participant underwent no medication changes and withdrew consent for study participation at week 24 without achieving virologic suppression.